Front. Med. Frontiers in Medicine Front. Med. 2296-858X Frontiers Media S.A. 10.3389/fmed.2021.645651 Medicine Original Research Spectrum and Clinical Characteristics of Symptomatic and Asymptomatic Coronavirus Disease 2019 (COVID-19) With and Without Pneumonia Zeng Huihui 1 Ma Yiming 1 Zhou Zhiguo 2 Liu Wenlong 3 Huang Peng 4 Jiang Mingyan 5 Liu Qimi 6 Chen Ping 1 Luo Hong 1 Chen Yan 1 * 1Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital of Central South University, Changsha, China 2Department of Respiratory Medicine, The First Hospital of Changsha, Changsha, China 3Department of Respiratory Medicine, Yueyang Second People's Hospital, Yueyang, China 4Department of Respiratory Medicine, Zhuzhou Central Hospital, Zhuzhou, China 5Department of Respiratory and Critical Medicine, Xiangtan Central Hospital, Xiangtan, China 6Department of Respiratory Medicine, The Second People's Hospital of Guilin, Guilin, China

Edited by: Bathri Narayan Vajravelu, MCPHS University, United States

Reviewed by: Yuhan Xing, The Chinese University of Hong Kong, China; Richa Singhal, University of Louisville, United States

 *Correspondence: Yan Chen chenyan99727@csu.edu.cn

This article was submitted to Infectious Diseases - Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine

 01 04 2021 2021 8 645651 23 12 2020 15 02 2021 Copyright © 2021 Zeng, Ma, Zhou, Liu, Huang, Jiang, Liu, Chen, Luo and Chen. 2021 Zeng, Ma, Zhou, Liu, Huang, Jiang, Liu, Chen, Luo and Chen

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Background: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has become a global pandemic. Based on symptoms, COVID-19 cases can be classified as symptomatic or asymptomatic. However, there is limited information about the differences between COVID-19 patients with and without pneumonia. Our study aimed to further discuss the spectrum and clinical characteristics of symptomatic and asymptomatic COVID-19 patients with and without pneumonia.

Methods: In China, all COVID-19 cases are hospitalized in designated hospitals until two continuous negative oropharyngeal swabs obtained, which allows the professional monitoring of symptoms and clinical characteristics. We stratified all COVID-19 cases in our database and evaluated clinical characteristics in different COVID-19 subgroups (symptomatic with pneumonia, symptomatic without pneumonia, asymptomatic with pneumonia, and asymptomatic without pneumonia).

Results: According to symptoms and laboratory and radiologic findings, COVID-19 cases were defined as symptomatic with pneumonia, symptomatic without pneumonia, asymptomatic with pneumonia, or asymptomatic without pneumonia. There were differences in the clinical characteristics and prognosis among the four groups. Both non-invasive mechanical ventilation (18, 4.2%) and invasive mechanical ventilation (11, 2.6%) were applied in only the symptomatic with pneumonia group. Likewise, extracorporeal membrane oxygenation and continuous renal replacement therapy were applied in only the symptomatic with pneumonia group. There were no differences in viral load, the durations of viral shedding, and hospitalization among the four groups.

Conclusion: We have defined a comprehensive spectrum of COVID-19 with and without pneumonia. The symptomatic with pneumonia group consumed more medical resources than the other groups, and extra caution and monitoring should be applied in this group. The asymptomatic COVID-19 group had a similar viral load and viral shedding duration as the symptomatic COVID-19 group.

 spectrum characteristics asymptomatic COVID-19 symptomatic pneumonia Introduction

Coronavirus disease 2019 (COVID-19) emerged since December 2019 in Wuhan, Hubei province, central-south China, and is an ongoing global pandemic (1). As of November 2, 2020, there were more than 45 million COVID-19 patients worldwide, and more than 1 million patients lost their lives (2). The causative pathogen has been identified as a novel enveloped RNA beta coronavirus with phylogenetic similarity to severe acute respiratory syndrome coronavirus (SARS-CoV) (3) and has been named SARS-CoV-2 by the World Health Organization. Antiviral drugs were effective for SARS-CoV-2 only in vitro, and a recent clinical trial of lopinavir–ritonavir, an antiviral therapy, was not associated with any benefits in COVID-19 patients (4). Because of pandemic transmission and ineffective therapeutics, early diagnosis and quarantine seem to be crucial to combat COVID-19. The spectrum of COVID-19 ranges from asymptomatic or mild, self-limiting respiratory tract illness to severe progressive pneumonia and acute respiratory distress syndrome (ARDS) (1, 5). Approximately 80% of COVID-19 patients have non-severe illness, but the asymptomatic ratio varies widely in the literatures, which could be explained by different definitions of asymptomatic COVID-19 cases and the late onset of symptoms (5–7) during the disease course. Despite inconsistencies in the asymptomatic case proportions, it is well-accepted that asymptomatic COVID-19 patients can serve as transmission sources (7–9).

SARS-CoV-2 relies on the angiotensin-converting enzyme 2 (ACE2) receptor for cellular entry, and the expression of ACE2 has been confirmed in nasal goblet cells and alveolar epithelial cells, indicating that SARS-CoV-2 can infect both the upper and lower airways (10). However, there is limited information about differences between upper airway and lower airway (pneumonia) infections in COVID-19 patients. To better understand and identify the spectrum of COVID-19, we conducted this retrospective study to discuss the clinical characteristics in different COVID-19 groups stratified by the presence or absence of symptoms and pneumonia.

 Methods Study Design

This study was approved and supervised by the Medical Research Ethics Committee of the Second Xiangya Hospital, Central South University. This retrospective study was performed at the Public Health Treatment Center of Changsha, People's Hospital of Junshan District, Loudi Central Hospital, People's Hospital of Lucheng District, Xiangtan Central Hospital, and People's Hospital of Yunyang District, which were designated COVID-19 hospitals in Hunan and Hubei provinces. COVID-19 patients were admitted to a designated hospital, once they were diagnosed with COVID-19. A total of 228 patients were hospitalized in Changsha, the closest neighboring capital city of Wuhan. COVID-19 was confirmed by real-time reverse transcription–polymerase chain reaction (RT-PCR) detecting SARS-CoV-2 as described previously (3). Open reading frame 1ab (ORF1ab) and nucleocapsid protein (N) were the two targeted genes simultaneously amplified and tested. Clinical samples were quantified and expressed as a cycle threshold value (Ct value), which detected ORF1ab and N as the two targeted genes. The viral load of patients' nasopharyngeal swab samples was estimated by Ct values of N gene, when RT-PCR results were considered positive at the first time. To analyze the characteristics and outcomes of symptomatic and asymptomatic COVID-19 patients with or without pneumonia, we reviewed medical records and enrolled all COVID-19 patients (n = 498) from the above designated hospitals who had been discharged or died before March 30.

The following medical information was obtained: demographics, symptoms during the whole course of COVID-19 (fever, cough, expectoration, dyspnea, temperature, and respiratory rate), laboratory findings (arterial blood pH, arterial blood Pao2, white blood cell count, neutrophils, lymphocyte count, and serum lactate dehydrogenase), chest computed tomography (CT) findings, comorbidities and concomitant diseases, duration of hospitalization, use of antivirus treatments, and concomitant treatments during admission (corticosteroids and antibiotics).

 Variables and Definitions

Temperature was examined at least three times a day, and fever was defined as an axillary temperature > 37.3°C (include 37.3°C). Chest CT was conducted every 3–5 days during hospitalization, and the classification of abnormal CT findings associated with COVID-19–related pneumonia followed those of previous research (11). Clinical improvement was defined as no fever for >3 days, the resolution of symptoms, and radiologic improvement (1). Patients were discharged after clinical improvement and the receipt of two negative continued SARS-CoV-2 RT-PCR tests with an interval of more than 24 h.

Severe COVID-19 was defined as a respiratory rate ≥30 breaths/min, blood oxygen saturation (Sao2) ≤93%, a Pao2/fraction of inspired oxygen (Fio2) ratio <300 mm Hg, and/or lung infiltrates in >50% of the lung field within 24–48 h (1). Patients with respiratory failure, septic shock, and/or multiple organ dysfunction/failure were defined as critical COVID-19 patients (1). All the critical patients were admitted into intensive care unit (ICU).

The duration of viral shedding for mild or moderate COVID-19 patients was defined as the time from the date of symptom onset to the date of the last negative result from two consecutive throat swab samples with an interval of more than 24 h, without positive result in subsequent test. The duration of viral shedding for asymptomatic COVID-19 patients was defined as the time from the first-time positive SARS-CoV-2 RT-PCR test to the date of the second consecutive negative RT-PCR results, with 24-h interval and without a positive subsequent test (12, 13).

According to the presence symptoms (fever, cough, expectoration, dyspnea, fatigue, muscle soreness, and headache), COVID-19 patients were divided into asymptomatic and symptomatic COVID-19 groups. Following the pneumonia guidelines from the American Thoracic Society (14), asymptomatic patients with normal chest CT findings during hospitalization were classified as the asymptomatic without pneumonia group. In contrast, asymptomatic patients with abnormal laboratory and radiologic findings during hospitalization were classified as the asymptomatic with pneumonia group. Likewise, symptomatic COVID-19 patients were classified into symptomatic with pneumonia groups and symptomatic without pneumonia groups. Symptoms, laboratory examination results, chest CT findings, and outcomes were confirmed by two independent pulmonologists.

 Statistical Analysis

Continuous variables are presented as medians [interquartile ranges (IQRs)], and categorical variables are presented as n (%). We used the Kruskal–Wallis test, Mann–Whitney U-test, χ2 test, or Fisher exact test to compare differences between groups. A two-sided α of < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS software (version 23.0; SPSS Inc., Chicago, IL).

 Results

In our study, 498 patients with confirmed COVID-19 were admitted to designated hospitals, and all of them were discharged or died before March 30. A total of 461 patients (92.6%) had symptoms and were included in the symptomatic group, whereas the other 37 patients (7.4%) were included in the asymptomatic group. Of the 461 symptomatic patients, 430 (93.3%) had abnormal laboratory and chest CT findings and were included in the symptomatic with pneumonia group, whereas the other 31 (6.2%) were included in the symptomatic without pneumonia group. Of the 37 asymptomatic COVID-19 patients, 23 (62.2%) had abnormal laboratory and chest CT findings and were classified in the asymptomatic with pneumonia group, whereas the other 14 (37.8%) were classified in the asymptomatic without pneumonia group (Figure 1). The greater frequency of pneumonia in the symptomatic group than in the asymptomatic group (p < 0.001 by χ2 test) supports the theory that symptomatic COVID-19 might be more likely to be associated with lower airway infection than with upper airway infection.

Flowchart of eligible patients.

 Demographic Characteristics and Reported Symptoms

The median age of the 430 symptomatic COVID-19 with pneumonia patients was 45.0 years (IQR, 34.0–57.0 years), and 171 (39.8%) of the 430 patients were male (Table 1). The median ages of the 31 symptomatic COVID-19 without pneumonia patients, 23 asymptomatic COVID-19 with pneumonia patients, and 14 asymptomatic COVID-19 without pneumonia patients were 35.0 years (17.0–50.0 years), 48.0 years (38.0–59.0 years), and 25.0 years (11.0–51.5 years), respectively (Table 1). Statistical analysis showed that COVID-19 patients without pneumonia were younger than COVID-19 patients with pneumonia (p = 0.001, Table 1). Of the 23 asymptomatic pneumonia patients, only 6 (26.1%) were male, presenting a significantly lower proportion of males than females (Table 1). There were no differences in comorbidities, except for a higher frequency of hypertension (39.1%) in the asymptomatic with pneumonia group, compared with the others (Table 1).

Epidemiological and clinical characteristics in symptomatic and asymptomatic COVID-19 cases.

Symptomatic COVID-19 Asymptomatic COVID-19
Items With pneumonia (n = 430) Without pneumonia (n = 31) With pneumonia (n = 23) Without pneumonia (n = 14) p-value
Age, years 45.0 (34.0–57.0)* 35.0 (17.0–50.0)* 48.0 (38.0–59.0) 25.0 (11.0–51.5)* 0.001
Sex, male 206 (47.9) 17 (54.8) 6 (26.1)* 7 (50.0) 0.175
Exposure to Wuhan 171 (39.8) 12 (38.7) 6 (26.1) 1 (7.1)* 0.055
Family clusters# 92 (47.9)* 13 (72.2) 8 (88.9) 5 (55.6) 0.018
Comorbidity 86 (20.0) 4 (12.9) 7 (30.4) 2 (14.3) 0.424
   Influenza A or B# 0 (0) 0 (0) 0 (0) 0 (0) NA
   Cardiovascular disease 17 (4.0) 2 (6.5) 1 (4.3) 0 (0) 0.790
   Diabetes mellitus 37 (8.6) 0 (0) 4 (17.4) 0 (0) 0.020
   Hypertension 63 (14.7) 4 (12.9) 9 (39.1)* 1 (7.1) 0.032
   COPD 12 (2.8) 1 (3.2) 0 (0) 0 (0) 0.374
   Chronic liver disease 14 (3.3) 0 (0) 0 (0) 0 (0) 0.173
   Chronic kidney disease 2 (0.5) 0 (0) 0 (0) 0 (0) 0.611
   Malignancy 4 (0.9) 0 (0) 1 (4.3) 1 (7.1) 0.028
   Cerebrovascular disease 9 (2.1) 0 (0) 0 (0) 0 (0) 0.278
   Rheumatic disease 3 (0.7) 0 (0) 0 (0) 0 (0) 0.533
Signs and symptoms at admission
   Temperature at admission, °C 36.8 (36.5–37.3)* 36.7 (36.3–37.0) 36.6 (36.5–37.0) 36.6 (36.4–36.9) 0.021
   Respiratory rate 20.0 (20.0–20.0)* 20.0 (20.0–20.0) 20.0 (20.0–20.0) 20.0 (18.0–20.0) 0.042
   Fever 312 (72.6) 18 (58.1) 0 (0) 0 (0) <0.001
   Cough 297 (69.1)** 14 (45.2) 0 (0) 0 (0) <0.001
   Expectoration 178 (41.4)** 7 (22.6) 0 (0) 0 (0) <0.001
   Dyspnea 36 (8.4) 0 (0) 0 (0) 0 (0) 0.012
   Fatigue 156 (36.3) 8 (25.8) 0 (0) 0 (0) <0.001
   Muscle soreness 56 (13.0) 5 (16.1) 0 (0) 0 (0) 0.016
   Headache 34 (7.9) 1 (3.2) 0 (0) 0 (0) 0.053

Values are presented as median (IQR) or number (percentage).

p < 0.05 compared with other groups combined,

p < 0.05 compared with symptomatic COVID-19 with pneumonia cases.

Data were only analyzed using cases from Changsha (n = 228); p-values were compared by Kruskal–Wallis test, χ2 test, Fisher exact test, or one-way analysis of variance.

COPD, chronic obstructive pulmonary disease; NA, not available.

Moreover, we found that the proportion of patients reporting an exposure history to Wuhan was significantly lower in the asymptomatic without pneumonia group (7.1%) than in the other groups (Table 1), implicating that asymptomatic patients without pneumonia were more likely to be secondary cases than index cases. We have only collected family cluster history in 228 COVID-19 patients from the Public Health Treatment Center of Changsha. The results showed that symptomatic COVID-19 patients with pneumonia were less likely to be family cluster cases (47.9%, Table 1) than their counterparts.

As expected, the symptomatic with pneumonia group had a higher rate of symptoms, including a higher body temperature at admission (°C) (36.8 [IQR, 36.5–37.3]) and respiratory rate at admission (rate per min) (20 [IQR, 20–20]), cough (69.1%), and expectoration (41.4%) than the other groups (Table 1).

 Laboratory and Radiographic Findings

Routine blood tests showed a higher white blood cell count (× 109 per L) (6.5 [IQR, 4.7–7.5]) and lymphocyte count (× 109 per L) (2.4 [IQR, 1.7–3.0]) in the asymptomatic without pneumonia group than in the other groups (Table 2). In contrast, the symptomatic with pneumonia group had a higher frequency of lymphocytopenia (37.7%) and lower platelet count (× 109 per L) (187.5 [IQR, 147.0–246.0]) than the other groups (Table 2). However, there were no differences in hemoglobin levels among groups.

Laboratory findings in symptomatic and asymptomatic COVID-19 cases.

Symptomatic COVID-19 Asymptomatic COVID-19
Items With pneumonia (n = 430) Without pneumonia (n = 31) With pneumonia (n = 23) Without pneumonia (n = 14) p-value
White blood cell count, × 109/L 4.6 (3.6–5.8)* 5.7 (4.0–6.8) 5.7 (4.8–7.8)* 6.5 (4.7–7.5)* 0.001
    <4 × 109/L 148 (34.4)* 9 (29.0) 3 (13.0)* 3 (21.4) 0.095
   >10 × 109/L 10 (2.3) 1 (3.2) 1 (4.3) 2 (14.3) 0.021
Neutrophil count, × 109/L 2.9 (2.2–3.8) 3.3 (2.2–3.8) 3.6 (3.0–4.5)* 3.4 (2.1–4.6) 0.167
Lymphocyte count, × 109/L 1.2 (0.8–1.6)* 1.8 (1.3–2.7)* 1.5 (1.3–2.0)* 2.4 (1.7–3.0)* <0.001
Lymphocytopenia 162 (37.7)* 4 (12.9)* 3 (13.0)* 3 (21.4) 0.001
Hemoglobin, g/L# 130.0 (119.0–140.0) 129.0 (119.8–147.8) 133.0 (127.0–151.0) 125.0 (119.0–139.5) 0.431
Platelet, × 109/L 187.5 (147.0–246.0)* 221.0 (163.5–246.0) 238.0 (217.0–305.0)* 232.5 (187.8–261.0) 0.002
Alanine aminotransferase, U/L 21.3 (15.0–30.4)* 17.7 (11.7–24.7)* 20.5 (16.3–23.4) 16.7 (15.1–45.1) 0.139
Aspartate aminotransferase, U/L 23.4 (18.8–31.0) 23.3 (18.7–28.0) 20.8 (17.8–24.9)* 24.1 (18.3–33.4) 0.249
Total bilirubin, mmol/L 11.0 (8.1–17.0) 9.6 (6.6–12.6) 10.7 (9.0–19.5) 11.2 (8.3–13.5) 0.296
Lactose dehydrogenase, U/L 177.1 (145.6–221.0)* 155.7 (138.5–173.5)* 146.2 (133.0–185.0)* 146.5 (128.0–198.3) 0.002
Creatinine, μmol/L 62.0 (49.0–76.0) 57.0 (38.8–75.6) 59.8 (49.9–73.0) 51.2 (29.1–66.1) 0.280
D-dimer, mg/L 0.31 (0.18–0.52)* 0.24 (0.12–0.37) 0.26 (0.17–0.37) 0.14 (0.09–0.24)* 0.009
Prothrombin time, s 12.0 (11.1–12.7)* 11.8 (11.1–12.8) 11.1 (10.3–12.4)* 11.8 (10.8–12.2) 0.066
Activated partial thromboplastin time, s 32.4 (29.2–35.6) 31.3 (30.3–33.7) 31.8 (29.6–36.8) 34.1 (32.0–36.1) 0.622
Creatine kinase, U/L 66.9 (43.0–104.9) 78.0 (58.6–94.7) 67.1 (57.0–109.0) 76.2 (50.3–104.9) 0.736
Erythrocyte sedimentation rate, mm/h# 44.0 (22.0–67.3)* 18.0 (11.0–28.5)* 33.0 (9.5–65.5) 19.0 (7.0–22.8)* 0.001
CT value of nucleic SARS-CoV-2 acid test 33.0 (27.6–35.8) 33.0 (28.8–36.3) 32.3 (29.2–36.3) 32.3 (24.6–35.9) 0.933

Values are presented as median (IQR) or number (percentage).

p < 0.05 compared with other groups combined.

Data were only analyzed using cases from Changsha (n = 228); p values were compared by Kruskal–Wallis test, χ2 test, Fisher exact test, or one-way analysis of variance.

Elevated alanine aminotransferase levels (U per L) and lactose dehydrogenase (U per L) were observed in the symptomatic with pneumonia group compared with the symptomatic without pneumonia group (21.3 [IQR, 15.0–30.4] vs. 17.7 [IQR, 11.7–24.7] and 177.1 [IQR, 145.6–221.0] vs. 155.7 [IQR, 138.5–173.5], respectively) (Table 2). Compared with those in the other groups, the symptomatic with pneumonia group had a significantly higher level of d-dimer (mg per L) (0.31 [IQR, 0.18–0.52]) (Table 2). In contrast, a significantly lower level of d-dimer was observed in the asymptomatic without pneumonia group (mg per L) (0.14 [IQR, 0.09–0.24]) than in the other groups (Table 2).

We also found a higher erythrocyte sedimentation rate (mm per hour) (44.0 [IQR, 22.0–67.3]) and C-reactive protein (CRP) (U per L) (8.6 [IQR, 2.8–24.0]) in symptomatic with pneumonia group than in the other groups, whereas the asymptomatic without pneumonia group had a lower level of CRP (U per L) (1.7 [IQR, 0.3–3.0]) than the other groups (Table 2). Accordingly, among the 228 COVID-19 patients from the Public Health Treatment Center of Changsha, symptomatic patients with COVID-19 with pneumonia were more likely to have procalcitonin levels > 0.05 ng per mL (54, 28.1%) than the others (Table 2).

Antigens of influenza A and B were detected in designed hospitals, but antibodies were not detected. Interestingly, the results showed that there was no patient suffering with influenza A or B during hospitalization.

CT scan was conducted repeatedly during the hospitalization. As previously described (11), the CT findings in pneumonia patients were varied, including ground-glass opacity, consolidation, subpleural brand, and so on (Figure 2).

CT findings of COVID-19 patients. (A) Enlargement of bronchi and vascular and mixed consolidation and GGO were found in this symptomatic COVID-19 with pneumonia patient. (B) There was absence of abnormality in CT scan of this symptomatic COVID-19 without pneumonia patient. (C) Although this asymptomatic pneumonia patient had absence of symptoms, the CT scan found enlargement of bronchi and vascular and subpleural GGO and band. (D) This asymptomatic COVID-19 without pneumonia patient was observed with normal radiographic presentation in CT scan.

 Treatments and Outcomes

Excluding 10 patients who were only treated with traditional Chinese medicine in the symptomatic with pneumonia group and 1 patient who was treated with traditional Chinese medicine in the asymptomatic without pneumonia group, 487 patients received antiviral treatment, including arbidol, lopinavir/ritonavir, interferon, ribavirin, and chloroquine phosphate. In total, 254 patients (51.0%) received antibiotics, indicating the presence of secondary or concomitant bacterial infection. The symptomatic with pneumonia group had higher frequencies of antibiotic use (54.2%) and corticosteroid use (28.8) than the other groups (Table 3).

Treatments and outcomes in symptomatic and asymptomatic COVID-19 cases.

Symptomatic COVID-19 Asymptomatic COVID-19
Items With pneumonia Without pneumonia With pneumonia Without pneumonia p-value
(n = 430) (n = 31) (n = 23) (n = 14)
Treatments
   Antiviral therapy 420 (97.7) 31 (100) 23 (100) 13 (92.9) 0.865
   Abidol 200 (46.5) 16 (51.6) 14 (60.9) 6 (42.9) 0.543
   Lopinavir/ritonavir 310 (72.1) 24 (77.4) 10 (43.5)* 8 (57.1) 0.022
   Interferon 259 (60.2) 24 (77.4) 14 (60.9) 8 (57.1) 0.295
   Ribavirin 44 (10.2) 2 (6.5) 2 (8.7) 1 (7.1) 0.876
   Chloroquine phosphate 53 (12.3) 2 (6.5) 4 (17.4) 2 (14.3) 0.635
   Antibiotic therapy 233 (54.2)* 11 (35.5) 7 (30.4)* 3 (21.4)* 0.004
   Administration of corticosteroids 124 (28.8)* 2 (6.5)* 0 (0)* 0 (0)* <0.001
   Non-invasive mechanical ventilation 18 (4.2) 0 (0) 0 (0) 0 (0) 0.121
   Invasive mechanical ventilation 11 (2.6) 0 (0) 0 (0) 0 (0) 0.229
   ECMO 7 (1.6) 0 (0) 0 (0) 0 (0) 0.339
   CRRT 9 (2.1) 0 (0) 0 (0) 0 (0) 0.278
Clinical outcomes
   Severe cases 61 (14.2)* 3 (9.7) 0 (0) 0 (0) 0.011
   Critical cases (admission to ICU) 46 (10.7)* 1 (3.2) 0 (0) 0 (0) 0.019
   ARDS 18 (4.2) 0 (0) 0 (0) 0 (0) 0.121
Death 3 (0.7) 0 0 0 0.533
Duration of viral shedding, days 14.0 (9.0–21.0) 15.0 (8.8–23.8) 13.0 (7.0–19.0) 13.0 (8.3–17.8) 0.524
Duration of hospitalization, days 16.0 (11.5–24.0) 16.0 (10.0–23.0) 16.0 (11.0–22.0) 12.0 (8.8–17.0)* 0.234

Values are presented as median (IQR) or number (percentage).

p < 0.05 compared with other groups combined; p-values were compared by Kruskal–Wallis test, χ2 test, Fisher exact test, or one-way analysis of variance.

ECMO, extracorporeal membrane oxygenation; CRRT, continuous renal replacement therapy; ARDS, acute respiratory distress syndrome; ICU, intensive care unit.

Both non-invasive mechanical ventilation (18, 4.2%) and invasive mechanical ventilation (11, 2.6%) were used in only the symptomatic with pneumonia group (Table 3). Likewise, extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy were employed in only the symptomatic with pneumonia group (Table 3). The above results indicated that patients in the symptomatic with pneumonia group suffered from more severe conditions and consumed more medical resources than those in the other groups.

All 64 severe cases occurred in symptomatic COVID-19 patients; 47 of them were critical cases and in ICU, of whom 18 developed ARDS and 3 died. Of the 430 symptomatic with pneumonia patients, 61 (14.2%) had severe COVID-19, and 46 (10.7%) were admitted to the ICU, implying that patients in the symptomatic with pneumonia group were more likely to develop severe COVID-19 and be admitted to the ICU than those in the other groups (Table 3). Interestingly, we did not find differences in the viral load, duration of viral shedding, and hospitalization among the groups (Tables 2, 3).

The follow-up of patients discharged from the Public Health Treatment Center of Changsha is ongoing. Only four of them were re-positive during 2 weeks after discharge, and all of them were from symptomatic COVID-19 with pneumonia. Moreover, continued SARS-CoV-2 RT-PCR tests showed that the contacts of the re-positive patients were not COVID-19 cases. Because the data were limited, the statistical analysis was not conducted in this study.

 Discussion

As in Middle East respiratory syndrome patients (15, 16), mounting evidence supports that presymptomatic (17, 18) or asymptomatic COVID-19 patients are infectious (6, 8, 19). In contrast with the amount of research about asymptomatic and symptomatic COVID-19 patients, there is limited research on the differences between COVID-19 patients with and without pneumonia. It is well-acknowledged that pneumonia should be confirmed by radiography findings (14). Therefore, this retrospective study describes the spectrum of COVID-19, including symptomatic COVID-19 with pneumonia, symptomatic COVID-19 without pneumonia, asymptomatic COVID-19 with pneumonia, and asymptomatic COVID-19 without pneumonia, mainly according to symptoms and CT findings. This study observed and identified characteristics and differences among the four groups, suggesting that not only symptoms, but also the presence or absence of pneumonia should be considered when evaluating the spectrum of COVID-19. Unlike some other presymptomatic or incubational cohorts (6, 17, 18), the asymptomatic COVID-19 patients in our study were discharged and monitored or evaluated according to symptoms and laboratory findings by professional healthcare workers during hospitalization, to ensure the absence of symptoms and laboratory and radiologic abnormalities during the whole disease process.

Because senior patients are vulnerable to pneumonia (14), the higher prevalence of pneumonia in the symptomatic group could be explained by the older age of the symptomatic patients. Lower levels of lymphocyte and white blood cells were observed in the symptomatic groups and were associated with better outcomes than those in the asymptomatic groups, implying that lymphocyte and white blood cells might play a protective role in COVID-19. The prevalence of hypertension was higher in the asymptomatic groups than in the symptomatic groups, suggesting that antihypertension treatment, especially ACE inhibitors might be effective for COVID-19.

A number of studies have demonstrated SARS-CoV-2 viral loads in the upper airway (19, 20) and that SARS-CoV-2 entry factors are highly expressed in upper airway cells (10). Moreover, Roman et al. (7) isolated live SARS-CoV-2 from upper airway specimens and found separate genotypes in the upper and lower airways samples. All of the above findings demonstrate that SARS-CoV-2 can infect the upper airway. Therefore, we speculate that COVID-19 without pneumonia might be only the SARS-CoV-2 upper airway infection. As expected, lower prevalence rates of severe cases and pneumonia were found in asymptomatic COVID-19 patients, and asymptomatic patients without pneumonia presented fewer abnormal laboratory findings and a lower risk of developing severe COVID-19 than symptomatic patients. The results suggested that SARS-CoV-2 infection in only the upper airway might be self-limiting, leading to a lack of symptoms and a favorable prognosis. Alba et al. (21) found targeted T-cell responses to SARS-CoV-2 in individuals not exposed to SARS-CoV-2, but possibly exposed to other coronaviruses. Therefore, we speculate that the asymptomatic COVID-19 patients without pneumonia might have been recently infected by other coronaviruses, resulting in the production of T cells targeting SARS-CoV-2, limiting the infected region and attenuating the severity of COVID-19. To save and make effective use of medicine sources, asymptomatic COVID-19 patients without pneumonia should be quarantined in primary hospitals or even Fangcang shelter hospitals (22), rather than tertiary hospitals if possible.

COVID-19 originated in Wuhan in November 2019, and exposure to Wuhan was considered important in the medical history of patients in previous studies (5, 23). The lower frequency of exposure to Wuhan in the asymptomatic without pneumonia group indicated a lower percentage of index cases in this group than in the other groups. Coronaviruses have the potential to mutate, and SARS-CoV-2 has exhibited patient-derived mutations and varying pathogenicity according to subtype (24, 25). Therefore, it is possible that SARS-CoV-2 in secondary patients has mutated, leading to decreased pathogenicity and asymptomatic COVID-19. Because of airborne transmission, family clusters play a role in SARS-CoV-2 spread (26, 27). Awareness of social distancing and personal protection caused by obvious symptoms in family members could explain the lower percentage of family clusters in the symptomatic with pneumonia group than in the other groups. On the other hand, the absence of influenza A or B in these COVID-19 patients also could be explained by the awareness of social distancing and personal protection.

Both the symptoms and laboratory findings in results support that symptomatic COVID-19 patients suffer from more severe disease than asymptomatic COVID-19 patients. A higher rate of ECMO and a higher frequency of ICU admission in the symptomatic with pneumonia group indicated not only the greater consumption of medical resources but also the need of additional monitoring in this group. In contrast, we did not find differences in viral load, viral shedding, and hospitalization durations between the symptomatic and asymptomatic groups as in previous studies (19, 28). The results suggested that asymptomatic COVID-19 might present similar pathogenicity and process of viral shedding as symptomatic COVID-19.

Asymptomatic COVID-19 with pneumonia patients also presented significant characteristics. Compared with the other patients, they are more likely to be male with hypertension and more frequently presented with lymphocytopenia and dysregulation of aminotransferase and prothrombin time. Although the asymptomatic with pneumonia subgroup showed favorable outcomes without ventilation and severe cases, statistical analysis could not find any difference between the only two pneumonia groups (symptomatic vs. asymptomatic). The limited sample size of asymptomatic with pneumonia might be a reason, and further study with larger asymptomatic with pneumonia cases is needed.

Because of a lack of significant clinical symptoms, using symptoms to screen for asymptomatic COVID-19 is difficult (17, 29, 30). In China, the Center for Disease Control and Prevention conducted SARS-CoV-2 PCR testing for all close contacts of COVID-19 patients (1). Because of the strict and comprehensive screening strategy, the prevalence of asymptomatic cases seems to be higher in our study than in other studies (17). As asymptomatic COVID-19 patients can be transmission sources (7–9), and our results showed that 7.4% of COVID-19 patients were asymptomatic, a more comprehensive screening strategy for COVID-19 is urgently needed. On the other hand, follow-up showed that there were four re-positive patients, and they were all from the symptomatic with pneumonia group. Because the data were limited, there is a need to collect more re-positive cases to discuss characteristics.

There are some limitations to this study. Because almost all the patients accepted antiviral treatment, it was possible that some presymptomatic COVID-19 patients did not develop symptomatic disease and were thus classified in the asymptomatic group. However, effective antiviral drugs targeting COVID-19 have not been identified thus far (31). Therefore, we considered the confusion of presymptomatic and asymptomatic COVID-19 patients under professional monitor during hospitalization might be rare. Because of the limited sample size and a lack of reliable evidences about Chinese traditional treatment against COVID-19, the authors did not exclude or analyze the Chinese traditional medicine–treated samples separately. Moreover, to assess the mutations and the infectivity of SARS-CoV-2, viral sequencing should be conducted in future studies.

 Conclusion

This spectrum of COVID-19 includes symptomatic COVID-19 with pneumonia, symptomatic COVID-19 without pneumonia, asymptomatic COVID-19 with pneumonia, and asymptomatic COVID-19 without pneumonia. The symptomatic with pneumonia group consumed more medical resources than the other groups, and extra caution of monitoring should be applied in this group. Asymptomatic COVID-19 case presented a similar viral load and viral shedding duration as symptomatic COVID-19 case.

 Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

 Ethics Statement

The studies involving human participants were reviewed and approved by the institutional ethics committee of The Second Xiangya Hospital (2020-010). Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

 Author Contributions

Every author contributed to reviewing the paper. HZ performed, designed the work, and drafted the manuscript. YM performed the statistical analyses. ZZ, WL, PH, MJ, and QL treated and monitored COVID-19 cases. HL and PC inspired the research questions and helped to draft the manuscript. YC was the principal investigator of the study and supervised the study and preparation of the manuscript. All authors contributed to the article and approved the submitted version.

 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 References Organization WH. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Geneva: WHO (2020). Organization WH. Coronavirus Disease 2019 (COVID-19): Situation Report, 76. Geneva. (2020). Cao B Wang Y Wen D Liu W Wang J Fan G . A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. (2020) 382:1787–99. 10.1056/NEJMoa200128232187464 Guan WJ Ni ZY Hu Y Liang WH Ou CQ He JX . Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. (2020) 32:1702–20. 10.1056/NEJMoa2002032 Nishiura H Kobayashi T Miyama T Suzuki A Jung S Hayashi K . Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). medRxiv. (2020). 10.1101/2020.02.03.2002024832179137 Ehmann KZ Drosten C Wendtner C Zange M Vollmar P Rosina Ehmann D . Virological assessment of hospitalized cases of coronavirus disease 2019. Nature. (2020) 581:465–9. 10.1038/s41586-020-2196-x Rothe C Schunk M Sothmann P Bretzel G Froeschl G Wallrauch C . Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. (2020) 382:970–1. 10.1056/NEJMc200146832003551 Bai Y Yao L Wei T Tian F Jin D-Y Chen L . Presumed asymptomatic carrier transmission of COVID-19. JAMA. (2020) 323:1406–7. 10.1001/jama.2020.2565 Sungnak W Huang N Bécavin C Berg M Queen R Litvinukova M . SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. (2020) 26:1–7. 10.1038/s41591-020-0868-632327758 Zhu N Zhang D Wang W Li X Yang B Song J . A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. (2020) 382:727–33. 10.1056/NEJMoa200101731978945 Xie X Zhong Z Zhao W Zheng C Wang F Liu J. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology. (2020) 296:200343. 10.1148/radiol.202020034332049601 Avanzato VA Matson MJ Seifert SN Pryce R Williamson BN Anzick SL . Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. (2020) 183:1901–12. e9. 10.1016/j.cell.2020.10.04933248470 Zhou R Li F Chen F Liu H Zheng J Lei C . Viral dynamics in asymptomatic patients with COVID-19. Int J Infect Dis. (2020) 96:288–90. 10.1016/j.ijid.2020.05.03032437933 Metlay JP Waterer GW Long AC Anzueto A Brozek J Crothers K . Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America. Am J Respirat Crit Care Med. (2019) 200:e45–67. 10.1164/rccm.201908-1581ST31573350 Hui DS Azhar EI Kim Y-J Memish ZA Oh M-d Zumla A. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis. (2018) 18:e217–27. 10.1016/S1473-3099(18)30127-029680581 Al-Ahmadi K Alahmadi M Al-Zahrani A. Spatial association between primary Middle East respiratory syndrome coronavirus infection and exposure to dromedary camels in Saudi Arabia. Zoo Public Health. (2020) 67:382–90. 10.1111/zph.1269732112508 Arons MM Hatfield KM Reddy SC Kimball A James A Jacobs JR . Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. (2020) 382:2081–90. 10.1056/NEJMoa200845732329971 Yu P Zhu J Zhang Z Han Y. A familial cluster of infection associated with the 2019 novel coronavirus indicating possible person-to-person transmission during the incubation period. J Infect Dis. (2020) 221:1757–61. 10.1093/infdis/jiaa07732067043 Zou L Ruan F Huang M Liang L Huang H Hong Z . SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. (2020) 382:1177–9. 10.1056/NEJMc200173732074444 Cheng PK Wong DA Tong LK Ip S-M Lo AC Lau C-S . Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet. (2004) 363:1699–700. 10.1016/S0140-6736(04)16255-715158632 Grifoni A Weiskopf D Ramirez SI Mateus J Dan JM Moderbacher CR . Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. (2020) 181:1489–501. 10.1016/j.cell.2020.05.01532473127 Chen S Zhang Z Yang J Wang J Zhai X Bärnighausen T . Fangcang shelter hospitals: a novel concept for responding to public health emergencies. Lancet. (2020) 395:1305–14. 10.1016/S0140-6736(20)30744-332247320 Li Q Guan X Wu P Wang X Zhou L Tong Y . Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. (2020) 382:1199–207. 10.1056/NEJMoa200131631995857 Yao H-P Lu X Chen Q Xu K Chen Y Cheng L . Patient-derived mutations impact pathogenicity of SARS-CoV-2. medRxiv. (2020). 10.2139/ssrn.3578153 Tang X Wu C Li X Song Y Yao X Wu X . On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev. (2020) nwaa036. 10.1093/nsr/nwaa036 Zhou X Li Y Li T Zhang W. Follow-up of asymptomatic patients with SARS-CoV-2 infection. Clin Microbiol Infect. (2020) 26:957–9. 10.1016/j.cmi.2020.03.02432489937 Chan JF-W Yuan S Kok K-H To KK-W Chu H Yang J . A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. (2020) 395:514–23. 10.1016/S0140-6736(20)30154-931986261 Lee S Kim T Lee E Lee C Kim H Rhee H . Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea. JAMA Inter Med. (2020) 180:1–6. 10.1001/jamainternmed.2020.386232780793 Chen N Zhou M Dong X Qu J Gong F Han Y . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. (2020) 395:507–13. 10.1016/S0140-6736(20)30211-732007143 Lai C-C Liu YH Wang C-Y Wang Y-H Hsueh S-C Yen M-Y . Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARSCoV-2): facts and myths. J Microbiol Immunol Infect. (2020) 53:404–12. 10.1016/j.jmii.2020.02.012 Sanders JM Monogue ML Jodlowski TZ Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. (2020) 323:1824–36. 10.1001/jama.2020.601932282022

Funding. This study was supported by the National Key Clinical Specialist Construction Programs of China; the National Natural Science Foundation of China 81400032; the Natural Science Foundation of Hunan Province 2019JJ50877; and Emergency Project of Prevention and Control for COVID-19 of Central South University 160260009.